Syndax Pharmaceuticals, Inc. beat EPS estimates 81% of the time across 16 reported quarters (13 beats, 3 misses), averaging +4.0% versus consensus. Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result | Call |
|---|---|---|---|---|---|
| Q2 FY26 | $-0.45 | $-0.55 | -22.2% | Miss | Q2 FY26 call |
| Q1 FY26 | $-0.59 | $-0.48 | +18.6% | Beat | |
| Q4 FY25 | $-0.64 | $-0.78 | -21.9% | Miss | Q4 FY25 call |
| Q3 FY25 | $-0.74 | $-0.70 | +5.4% | Beat | |
| Q2 FY25 | not reported | $-0.83 | not reported | not reported | Q2 FY25 call |
| Q1 FY25 | $-1.04 | $-0.98 | +5.8% | Beat | |
| Q4 FY24 | $-1.08 | $-1.10 | -1.9% | Miss | |
| Q3 FY24 | $-1.13 | $-0.98 | +13.3% | Beat | |
| Q2 FY24 | $-0.91 | $-0.80 | +12.1% | Beat | |
| Q1 FY24 | $-0.96 | $-0.85 | +11.5% | Beat | |
| Q4 FY23 | not reported | $1.00 | not reported | not reported | |
| Q3 FY23 | $-0.80 | $-0.73 | +8.8% | Beat |
Back to SNDX overview · SNDX holders · SNDX KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.